Compare ARQT & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | REAL |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.9B |
| IPO Year | 2020 | 2019 |
| Metric | ARQT | REAL |
|---|---|---|
| Price | $21.29 | $8.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $34.00 | $17.00 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 43.55 |
| EPS | ★ N/A | N/A |
| Revenue | $376,072,000.00 | ★ $692,845,000.00 |
| Revenue This Year | $34.46 | $14.30 |
| Revenue Next Year | $29.77 | $10.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | 15.38 |
| 52 Week Low | $11.86 | $4.61 |
| 52 Week High | $31.77 | $17.39 |
| Indicator | ARQT | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 29.19 |
| Support Level | $19.60 | $7.21 |
| Resistance Level | $21.84 | $8.18 |
| Average True Range (ATR) | 0.87 | 0.53 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 6.71 | 2.01 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.